CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advances Drug Candidate to Fight Aggressive Brain Cancer Amid Difficult Era for Market
August 4, 2022
CNS Pharmaceuticals is a U.S.-based drug innovator developing novel chemotherapy agents capable of taking the fight against cancerous tumors across the blood-brain barrier to directly attack cancerous growths of the central nervous system The company’s lead candidate is an anthracycline named Berubicin, which has previously shown promise among glioblastoma (“GBM”) patients in a safety study […]
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment
August 2, 2022
CNS Pharmaceuticals is undertaking a Berubicin clinical development program targeting glioblastoma multiforme (“GBM”), the most common and devastating primary malignant brain tumor GBM has an incidence rate of 3.21 per 100,000 in the U.S. and up to 5 per 100,000 globally, with studies noting that the latter figure is rising CNS recently received approval for […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Urges Shareholders to Vote in Favor of Proxy Proposals for Upcoming Annual Meeting
July 25, 2022
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today urged shareholders to vote in favor of the proposals outlined in its definitive proxy statement for the upcoming annual shareholder meeting to be held Wednesday, […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Expanding Patient Eligibility in Potentially Pivotal Berubicin Trial
July 20, 2022
CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that its global clinical trial for a potentially pivotal brain cancer treatment will expand patient eligibility following an amendment to its protocol for the study. “CNS has been enrolling patients in its phase II clinical trial for novel drug candidate Berubicin, which has shown promise in fighting the aggressive […]
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expands Patient Eligibility for Brain Cancer Drug Trial, Receives Approval from U.S. FDA for Protocol Amendment
July 11, 2022
Novel brain cancer drug developer CNS Pharmaceuticals, Inc. has received approval from the U.S. FDA for a Protocol Amendment that expands patient eligibility for participation in its potentially pivotal Phase 2 clinical trial for a novel drug candidate that targets the nearly 100 percent fatal cancer glioblastoma (“GBM”) CNS is developing the drug candidate Berubicin […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures FDA Approval for Protocol Amendment to Ongoing Potentially Pivotal Berubicin Trial
June 23, 2022
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced its receipt of approval from the U.S. Food and Drug Administration (“FDA”) for its ongoing potentially pivotal global study evaluating the efficacy and safety […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Presents Overview of Ongoing Clinical Trial at ASCO Annual Meeting
June 8, 2022
CNS Pharmaceuticals (NASDAQ: CNSP) Scientific Advisory Board member Sigmund Hsu, MD, presented at the American Society of Clinical Oncology (“ASCO”) annual meeting. Hsu’s presentation focused on the company’s ongoing clinical trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”). CNS Pharmaceuticals is a biopharmaceutical company specializing in the development of novel treatments for […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright Global Investment Conference
May 24, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its CEO John Climaco will be participating at the H.C. Wainwright Global Investment Conference. The event is slated to take place May 23-26, 2022, virtually and […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Among Most Powerful of Chemotherapy Drugs
May 23, 2022
CNS Pharmaceuticals’ (NASDAQ: CNSP) novel anthracycline Berubicin, which has been developed to treat diseases with unmet need such as the deadly glioblastoma (“GBM”), appears to be the first anthracycline chemotherapy agent to successfully cross the blood-brain barrier in targeting tumors of the central nervous system. “Berubicin was the drug candidate subject of a small-scale phase […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract to be Presented at American Society of Clinical Oncology 2022 Annual Meeting
May 18, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced acceptance of its abstract for poster presentation at the American Society of Clinical Oncology (“ASCO”) 2022 Annual Meeting. Being held virtually and in Chicago, Illinois, the event […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2022 Financial, Corporate Update
May 16, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released its first quarter 2022 financial report along with key updates on company strategies. The report pointed to recent approvals of a potentially pivotal Berubicin study in Europe […]
Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)
May 11, 2022
CNS Pharmaceuticals is developing a proprietary drug candidate that has the potential to deliver a novel solution for unmet medical needs in treating an incurable brain cancer CNS’s drug candidate is called Berubicin, a powerful anthracycline that appears to be the first such chemotherapy agent able to successfully cross the blood-brain barrier Berubicin dosing has […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Demonstrating ‘Encouraging Promise in Treatment of GBM’
May 5, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical cancer drug developer, recently reported new advances in its rollout of a global clinical trial described as “potentially pivotal” in producing a treatment for an aggressive brain cancer, glioblastoma multiforme (“GBM”). On average, GBM is nearly 100% fatal just over a year into diagnosis. “CNS announced that France’s regulatory […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study
April 28, 2022
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”). The company today announced its receipt of approval from the Spanish Agency for Medicines and Health Products (“AEMPS”) Competent Authority and from the CElm Provincial de Sevilla […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Focused on Advancing Research on Treatments for GBM, Other Cancers
April 22, 2022
CNS Pharmaceuticals (NASDAQ: CNSP) is leading the charge toward advancing research on the treatment for glioblastoma multiforme (“GBM”) as well as other primary and metastatic brain and CNS cancers. Last year, the company commenced a potentially pivotal clinical trial of its lead product candidate, Berubicin, for the treatment of GBM, dosing its first patients in […]
European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug
April 13, 2022
Novel brain cancer drug developer CNS Pharmaceuticals is developing a proprietary pharmaceutical candidate called Berubicin for the treatment of glioblastoma multiforme (“GBM”) CNS has received Fast Track designation for Berubicin, which will allow the company more frequent communications with the FDA CNS has initiated a global potentially pivotal clinical trial to evaluate Berubicin in treating […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event
April 12, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be part of a moderated fireside chat during the Virtual Investor Glioblastoma Multiforme (“GBM”) Spotlight event on April 14, 2022. The chat is scheduled for 11:30 a.m. ET and […]
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers
April 11, 2022
CNS Pharmaceuticals is a clinical stage biotechnology company focused on the development of novel treatments for brain tumors The company’s lead product candidate, Berubicin, is a novel anthracycline that is designed to cross the blood-brain barrier The blood-brain barrier ordinarily hinders the vascular delivery of therapeutic substances to brain tumors By crossing this protective barrier, […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from France EC and ANSM Competent Authority for Potentially Pivotal Study of Berubicin
April 6, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced its receipt of approval from the National Agency for the Safety of Medicine and Health Products (“ANSM”) Competent Authority and from the People Protection Ethics Committee […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Key Approval for Pivotal Study of Berubicin
April 5, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has received key approval for a planned study. The approval came from Swissmedic, the Swiss agency for therapeutic products. CNSP can now move forward with its potentially pivotal study […]
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco Shares Company Highlights, Goals at 2022 Virtual Growth Conference Presented by Maxim Group LLC
April 4, 2022
The three-day event showcased CNS through corporate presentation, fireside chat, and live question and answer sessions CNS has been granted both Orphan Drug Designation and Fast Track status from the FDA for Berubicin in 2020 and 2021, respectively CNS initiated a potentially pivotal global trial of Berubicin for recurrent Glioblastoma Multiforme (“GBM”) with the dosing […]
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reiterates Commitment to Operational Excellence, Advancing Berubicin Recognition
March 31, 2022
In a video message to shareholders, CEO John Climaco detailed the operational and clinical progress made by lead drug candidate Berubicin despite market volatility and share price fluctuations CNS is currently enrolling patients into a potentially pivotal global drug trial of Berubicin for recurrent glioblastoma multiforme Interim analysis of the trial is currently expected as […]
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Update on Advances in Brain Cancer Drugs and Operational Financials
March 29, 2022
Texas-based CNS Pharmaceuticals is a novel brain cancer drug developer that is building a series of global clinical trials for its lead drug candidate, Berubicin CNS began dosing patients in a global trial last September to evaluate Berubicin in treating glioblastoma multiforme (“GBM”), currently an incurable brain cancer CNS received FDA Fast Track designation for […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate at the 2022 Virtual Growth Conference
March 23, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that its CEO John Climaco will participate at the 2022 Virtual Growth Conference. The event, presented by Maxim Group LLC and hosted by M-Vest, is slated […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Significant Milestone in Advancing Berubicin
March 17, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. The company’s CEO John Climaco provided a corporate presentation and participated in a moderated questions and answer session during […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reiterates Progress for Lead Product Candidate, Addresses Recent Share Price Activity in Video to Shareholders
March 9, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today released a video to shareholders that reiterates its operational and clinical progress for lead product candidate, Berubicin, and addresses recent share price activity. “The divergence that exists […]
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gives Corporate Presentation, Q&A Session at Virtual Investor 2022 Top Picks Conference
March 7, 2022
The company also participated in the H.C. Wainwright BioConnect Conference earlier in January CNS Pharmaceuticals recently received approval from swissethics for a pivotal Berubicin and GBM clinical trial The five-year survival rate for GBM is only 6.8%, with the average patient population surviving 12 to 18 months after diagnosis CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 2021 Financial Results, Corporate Update
March 3, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the year ended Dec. 31, 2021. The company also provided a clinical update of its anti-cancer drug candidates currently in development for […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Laying Robust Foundation for Potentially Pivotal Global Trial
February 2, 2022
CNS Pharmaceuticals (NASDAQ: CNSP) recently received approval from swissethics, the umbrella organization of the cantonal Ethics Committees in Switzerland. The first from a European Ethics Committee, the approval marks a significant milestone for the company as it journeys toward its potentially pivotal study of Berubicin, an anthracycline, for the treatment of Glioblastoma Multiforme (“GBM”). The […]
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Marks Significant Milestone in Pursuit of Berubicin Approval for Global GBM Treatment, Raises $11.5 Million from Private Placement
January 25, 2022
CNS Pharmaceuticals received approval from swissethics for its potentially pivotal study of Berubicin, a novel anthracycline for the treatment of Glioblastoma Multiforme (“GBM”) The approval is the first from a European Ethics Committee The company, which dosed the first patients in its Berubicin program in September, has selected multiple clinical sites across the U.S., Spain, […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor 2022 Top Picks Conference
January 20, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that its CEO John Climaco will participate in the Virtual Investor 2022 Top Picks Conference at 11:00 a.m. ET on Wednesday, Jan. 26, 2022. As part […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Closes on $11.5M Private Placement
January 11, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has closed on its previously announced private placement. The company announced that the placement was comprised of 12,105,264 shares of common stock (or prefunded warrants) and warrants at a […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate at H.C. Wainwright BioConnect Conference
January 7, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, announced that CEO John Climaco will present at the upcoming H.C. Wainwright BioConnect Conference. The conference is slated for Jan. 10-13, 2022. Interested parties who have registered for the […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Agreements Totaling $11.5M for Gross Proceeds
January 6, 2022
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (“CNS”), has entered into securities purchase agreements with several institutional and accredited investors. The agreements outline the issue of more than 12 million shares of common stock, prefunded warrants […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Switzerland Ethics Committee Approval of Pivotal Berubicin Study
December 2, 2021
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has received approval from the Switzerland Ethics Committee (swissethics) — the first approval of its kind from a European ethics committee — for its study of Berubicin. Exclusive to […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Roundtable
November 16, 2021
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the Virtual Investor Roundtable Event, scheduled for Nov. 18, 2021. The CNSP overview, presented by CNS Pharmaceuticals CEO John Climaco and chief medical officer Sandra L. […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Berubicin’s Impressive Potential in Syndicated Broadcast
October 11, 2021
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Group of Patients in Potentially Pivotal Trial
September 30, 2021
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced the dosing of the first patients in its Berubicin clinical development program for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2021 Financial Results, Provides Business Outlook
August 13, 2021
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the quarter ended June 30, 2021. The company also provided a clinical update of its anti-cancer drug candidates currently in development for […]
InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Clear Opportunity to Bring Impactful Therapy to GBM Patients
July 28, 2021
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. Over recent months, the company has achieved several milestones demonstrating its operational, financial and strategic strengths and continuous de-risking of its lead candidate Berubicin clinical program. “The company […]